TY - JOUR T1 - [HLA- haploidentical donor hematopoietic transplantation for severe aplastic anemia achieved comparable outcomes with HLA- unrelated donor transplantation]. AU - Lu,Yue, AU - Wu,Tong, AU - Cao,Xingyu, AU - Zhao,Yanli, AU - Liu,Deyan, AU - Sun,Ruijuan, AU - Xiong,Min, AU - Wei,Zhijie, AU - Zhang,Jianping, AU - Zhou,Jiarui, AU - Lu,Daopei, PY - 2016/2/16/entrez PY - 2016/2/16/pubmed PY - 2016/7/7/medline SP - 35 EP - 8 JF - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi JO - Zhonghua Xue Ye Xue Za Zhi VL - 37 IS - 1 N2 - OBJECTIVE: To evaluate the efficacy of HLA- haploidentical donor hematopoietic transplantation (Haplo- HSCT)for severe aplastic anemia (SAA)by compared with the same period of unrelated donor transplantation (UD- HSCT). METHODS: Of a cohort of 50 SAA patients between September 2012 and July 2014, 26 patients underwent UD- HSCT and 24 patients Haplo- HSCT. RESULTS: OS rate was 91.3% with a median follow-up of 9 (2-26)months. According to transplant type, there was no significant difference between UD- and Haplo-HSCT (96.1%vs 86.0%,P=0.30). 3 of 50 (6%)patients had primary engraft failure. Haplo- HSCT developed higher significantly incidence of Ⅱ- Ⅳ aGVHD (37.5%vs 3.83%,P=0.003)and cGVHD (37.5%vs 15.3%,P=0.030)than UD-HSCT. Haplo-HSCT also had significantly higher incidences of CMV viremia (78.2%vs 46.1%,P=0.005)and EBV viremia (43.1%vs 16.0%,P=0.040), respectively than UD-HSCT. But the incidences of hemorrhagic cystitis were similar between two transplant types (39.1%vs 23.0%,P=0.120). CONCLUSION: This study showed favorable outcome of Haplo-HSCT for SAA, which was comparable with UD-HSCT. SN - 0253-2727 UR - https://www.unboundmedicine.com/medline/citation/26876251/[HLA__haploidentical_donor_hematopoietic_transplantation_for_severe_aplastic_anemia_achieved_comparable_outcomes_with_HLA__unrelated_donor_transplantation]_ L2 - http://journal.yiigle.com/LinkIn.do?linkin_type=pubmed&issn=0253-2727&year=2016&vol=37&issue=1&fpage=35 DB - PRIME DP - Unbound Medicine ER -